AXSOME THERAPEUTICS INC
NASDAQ: AXSM (Axsome Therapeutics, Inc.)
Last update: 1 hour ago150.36
-0.84 (-0.56%)
| Previous Close | 151.20 |
| Open | 152.13 |
| Volume | 359,541 |
| Avg. Volume (3M) | 542,834 |
| Market Cap | 7,580,044,800 |
| Price / Earnings (Forward) | 625.00 |
| Price / Sales | 13.11 |
| Price / Book | 102.18 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | -64.39% |
| Operating Margin (TTM) | -45.67% |
| Diluted EPS (TTM) | -5.76 |
| Quarterly Revenue Growth (YOY) | 62.00% |
| Total Debt/Equity (MRQ) | 397.02% |
| Current Ratio (MRQ) | 2.03 |
| Operating Cash Flow (TTM) | -118.32 M |
| Levered Free Cash Flow (TTM) | -20.98 M |
| Return on Assets (TTM) | -26.17% |
| Return on Equity (TTM) | -282.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Axsome Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 16.31% |
| % Held by Institutions | 76.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wellington Management Group Llp | 30 Sep 2025 | 1,334,560 |
| Macquarie Group Ltd | 30 Sep 2025 | 1,084,536 |
| Price T Rowe Associates Inc /Md/ | 30 Sep 2025 | 1,037,448 |
| Deep Track Capital, Lp | 30 Sep 2025 | 900,000 |
| Fairmount Funds Management Llc | 30 Sep 2025 | 815,176 |
| Eventide Asset Management, Llc | 30 Sep 2025 | 746,398 |
| Alethea Capital Management, Llc | 30 Sep 2025 | 670,883 |
| Orbimed Advisors Llc | 30 Sep 2025 | 531,800 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 205.00 (Guggenheim, 36.34%) | Buy |
| Median | 190.50 (26.70%) | |
| Low | 154.00 (Needham, 2.42%) | Buy |
| Average | 184.50 (22.71%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 133.45 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 06 Nov 2025 | 202.00 (34.34%) | Buy | 139.41 |
| Guggenheim | 04 Nov 2025 | 205.00 (36.34%) | Buy | 134.93 |
| HC Wainwright & Co. | 04 Nov 2025 | 185.00 (23.04%) | Buy | 134.93 |
| Morgan Stanley | 04 Nov 2025 | 196.00 (30.35%) | Buy | 134.93 |
| 20 Oct 2025 | 194.00 (29.02%) | Buy | 131.60 | |
| Needham | 04 Nov 2025 | 154.00 (2.42%) | Buy | 134.93 |
| RBC Capital | 04 Nov 2025 | 198.00 (31.68%) | Buy | 134.93 |
| Wells Fargo | 04 Nov 2025 | 157.00 (4.42%) | Buy | 134.93 |
| 03 Sep 2025 | 163.00 (8.41%) | Buy | 122.00 | |
| B. Riley Securities | 01 Oct 2025 | 179.00 (19.05%) | Buy | 118.57 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |